Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus SCANLUX 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus SCANLUX 370.
CONRAY 43 vs SCANLUX-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent